Sichuan Biokin Stock Hits Day Low of CNY 301.11 Amid Price Pressure

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 5.96% on July 17, 2026. The stock reached an intraday low of CNY 301.11, reflecting a challenging trading environment for the company. In terms of performance metrics, Sichuan Biokin has shown a mixed performance over various time frames. While the stock has gained 36.09% over the past month, it has underperformed in the year-to-date period, with a decline of 3.13%. Comparatively, the China Shanghai Composite index has also faced challenges, declining by 5.16% year-to-date. Financially, the company reported net sales of CNY 2,065.9 million for the first nine months, marking a substantial decrease of 63.52%. Additionally, the net profit for the same period was reported at CNY -500.37 million, reflecting a growth decline of 112.34%. The operating cash flow has also reached a low of CNY -2,331.46 million, indicating potential liquidity concerns. As a large-cap player in the Pharmaceuticals & Biotechnology sector, Sichuan Biokin's current market capitalization stands at CNY 21,049 million.